S
Stoke Therapeutics Inc (STOK)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$26.63
-0.05 (-0.19%)
Market Cap: $1.75B
Last updated: Nov 17, 2026 at 11:06 AM ET
Stoke Therapeutics Inc (STOK) Valuation Multiples
Stoke Therapeutics (STOK) trades at 64.5x sales and 5.2x book value. Its P/S of 64.5x is above its 5-year median of 31.6x. Its forward P/E is 204.1x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 204.1x |
| Price to sales | 64.5x |
| Price to book | 5.2x |
| PEG | N/A |
| FCF yield | -11.8% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 64.5x | 31.6x | N/A |
| P/B | 5.2x | 2.9x | N/A |
Valuation History
Over the 4 of the 7 year ends shown that have a P/S, its P/S ranged from 10.0x in 2025 to 28.9x in 2022. 2025 was the lowest of those years.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $31.74 | 10.0x | 5.3x |
| 2024 | $11.03 | 16.7x | 2.7x |
| 2023 | $5.26 | 26.0x | 1.5x |
| 2022 | $9.23 | 28.9x | 2.0x |
| 2021 | $23.99 | N/A | 4.1x |
| 2020 | $61.93 | N/A | 7.6x |
| 2019 | $28.32 | N/A | 3.2x |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About STOK
What is STOK's forward P/E ratio?
Stoke Therapeutics has a forward P/E ratio of 204.1x.
Is STOK stock overvalued?
GNG's valuation label for STOK is Overvalued.
What is STOK's price to sales ratio?
Stoke Therapeutics has a price to sales ratio of 64.5x.
STOK pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors